MT-II (Melanotan II)

MT-II (Melanotan II) is a synthetic peptide that activates melanocortin receptors and is often discussed in relation to tanning and sexual function in experimental or non-regulated markets.

Many uses described in informal materials are outside the scope of approved medicines, and product quality and regulatory oversight vary widely between regions and suppliers.

MT-II acts on melanocortin receptors, including those involved in skin pigmentation and certain central nervous system pathways. High-level effects may include:

• Influencing melanin production in the skin
• Interacting with appetite and sexual function pathways in the brain

The balance of these effects, and how they vary between individuals, remains an area of ongoing research and debate.

In many jurisdictions, MT-II is not an approved drug for cosmetic tanning or sexual function and may be encountered primarily in research or informal markets.

Any consideration of MT-II should take into account regulatory status, potential risks, and the availability of better-characterized options in approved therapeutic areas.

Reported effects include flushing, nausea, darkening of moles or new pigmented lesions, and changes in libido. Long-term safety, including dermatologic and cardiovascular outcomes, is not well established.

Given these uncertainties, risk–benefit discussions are particularly important and should be guided by clinicians.

MT-II is a potent melanocortin agonist. Protocols described in user communities emphasize extreme caution due to the risk of nausea and side effects.

Warning: High doses can cause severe nausea, spontaneous erections, and darkening of moles. User reports strongly advise against exceeding 1 mg per dose.

MT-II is sold almost exclusively as lyophilized powder for reconstitution and subcutaneous injection, and increasingly as an unapproved nasal spray. Neither format has published pharmacokinetics, and the nasal route in particular revives a delivery method that the related bremelanotide programme abandoned because absorption varied too widely. A 2025 case report describes a 22-year-old woman who developed an anterior maxillary mass after using a Melanotan II nasal spray for tanning; histology confirmed mucosal malignant melanoma, treated with surgical resection and ongoing immunotherapy (Int J Oral Maxillofac Surg 2025). A single case cannot establish causation, but it is a reason the nasal format deserves more scrutiny, not less.

Two comparisons matter more than any blend. Melanotan I (afamelanotide) is the MC1-selective sibling that completed randomised trials and was approved as a 16 mg implant for erythropoietic protoporphyria. Bremelanotide (PT-141) is the refined derivative that completed phase 3 and was approved as Vyleesi, whose label states it is not indicated for men, postmenopausal women, or to enhance sexual performance (DailyMed). MT-II is the version of this chemistry that development passed over, and vendor "tan and libido" blends combining it with either relative stack two melanocortin agonists with no combination data behind them.

Research on melanocortin agonists has examined effects on pigmentation, appetite, and sexual function. For MT-II specifically, much of the available information comes from small studies and practice reports rather than large, long-term trials.

High-level summaries should therefore be treated as orientation rather than as a basis for clinical decisions.

For deeper dives on this peptide, see:

• MT-II (Melanotan II) benefits and areas of interest
• MT-II (Melanotan II) side effects and safety context
• MT-II (Melanotan II) dosing concepts (educational)
• MT-II (Melanotan II) research and evidence overview

Is Melanotan II legal or approved anywhere? It is not approved by the FDA or any comparable regulator for any indication. A 2025 case report in the International Journal of Oral and Maxillofacial Surgery notes that Melanotan II is unlicensed and its sale is illegal in the United Kingdom and many other countries (Alsabbagh et al. 2025). Legality varies by jurisdiction and possession rules differ from sale rules; the constant is that no regulator has evaluated it.

Has Melanotan II ever been tested for tanning? No. The only controlled human trial measured erections, not pigmentation: ten men with psychogenic erectile dysfunction in a double-blind placebo crossover study at 0.025 mg/kg, in which 8 of 10 developed clinically evident erections and mean tip rigidity above 80% lasted 38.0 versus 3.0 minutes on placebo (p=0.0045) (Wessells et al., J Urol 1998). For the use that accounts for nearly all consumption, the published record is dermatology case reports rather than efficacy studies.

Why does it cause spontaneous erections? Because it is a non-selective melanocortin agonist and hits central MC4R circuits along with the MC1 receptors that produce pigment. That effect is not incidental — it is what redirected the entire development programme toward bremelanotide, which the FDA approved as Vyleesi. The unwanted extreme of the same effect is ischemic priapism; one reported case required surgical penoscrotal decompression after aspiration and phenylephrine failed (Mallory et al., Sex Med 2021). Priapism lasting more than a few hours is a medical emergency.

Is a melanotan tan protective against sunburn or skin cancer? No study supports that, and the pigmentary literature runs the other way. Published reports document melanoma in situ associated with melanotan use (Ong and Bowling 2012) and new atypical melanocytic naevi after two injections (Reid et al. 2013). Darkening existing moles also degrades the visual cues used to detect melanoma early — which is why the approved drug in this class requires twice-yearly full-body skin examinations.

How is it different from Melanotan I and PT-141? Melanotan I (afamelanotide) is MC1-selective and is an approved 16 mg implant for erythropoietic protoporphyria. PT-141 (bremelanotide) is a refined derivative approved for hypoactive sexual desire disorder in premenopausal women. MT-II is the broad, unrefined parent compound that both were developed away from — it keeps every effect its relatives were engineered to separate, including the nausea that appeared in 40% of bremelanotide-treated patients versus 1.3% on placebo in phase 3 (Vyleesi label).